Parkman Healthcare Partners LLC acquired a new position in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 450,000 shares of the company's stock, valued at approximately $3,150,000. Parkman Healthcare Partners LLC owned 0.12% of LifeStance Health Group at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Paloma Partners Management Co acquired a new stake in LifeStance Health Group during the third quarter worth about $176,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in LifeStance Health Group by 10.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 516,819 shares of the company's stock worth $3,618,000 after buying an additional 48,634 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in LifeStance Health Group by 31.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,105 shares of the company's stock valued at $169,000 after buying an additional 5,767 shares during the period. MetLife Investment Management LLC increased its holdings in LifeStance Health Group by 14.3% in the third quarter. MetLife Investment Management LLC now owns 80,422 shares of the company's stock valued at $563,000 after buying an additional 10,084 shares in the last quarter. Finally, Townsquare Capital LLC acquired a new position in shares of LifeStance Health Group in the third quarter worth about $73,000. 85.50% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. UBS Group dropped their target price on LifeStance Health Group from $9.00 to $7.50 and set a "neutral" rating on the stock in a research report on Thursday, August 15th. Barclays raised their price objective on LifeStance Health Group from $6.00 to $7.00 and gave the company an "underweight" rating in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $8.50.
Read Our Latest Stock Report on LFST
Insider Activity at LifeStance Health Group
In other LifeStance Health Group news, Director Robert Bessler sold 75,000 shares of the company's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $7.54, for a total transaction of $565,500.00. Following the transaction, the director now directly owns 1,424,447 shares in the company, valued at $10,740,330.38. This represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.60% of the stock is currently owned by insiders.
LifeStance Health Group Price Performance
Shares of NASDAQ:LFST traded down $0.13 during trading on Wednesday, reaching $7.33. The stock had a trading volume of 1,035,274 shares, compared to its average volume of 1,524,732. The stock has a market cap of $2.80 billion, a PE ratio of -28.77 and a beta of 1.28. The business has a fifty day moving average price of $7.11 and a 200-day moving average price of $6.27. LifeStance Health Group, Inc. has a 1-year low of $4.64 and a 1-year high of $9.20. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The company had revenue of $312.70 million for the quarter, compared to analyst estimates of $302.25 million. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The firm's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.17) earnings per share. On average, equities analysts forecast that LifeStance Health Group, Inc. will post -0.22 earnings per share for the current fiscal year.
LifeStance Health Group Profile
(
Free Report)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Featured Stories
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
